BEIJING, February 19, 2025 — Beijing Byongen Therapeutics Co., Ltd. (Byongen Therapeutics) and Beijing Genecradle Therapeutics Technology Co., Ltd. (Genecradle Therapeutics) today announced a strategic partnership to co-develop a next-generation gene therapy for Duchenne Muscular Dystrophy (DMD). This collaboration merges Byongen’s cutting-edge AAV capsid engineering with Genecradle’s deep expertise in Dystrophin optimization and clinical translation to address the critical unmet needs of the DMD community.
DMD is a devastating X-linked genetic disorder caused by mutations in the DMD gene, resulting in the absence of functional dystrophin protein. This leads to progressive muscle wasting, loss of mobility in early childhood, and life-threatening cardiac or respiratory complications by early adulthood. While current standards of care manage symptoms, there remains a profound global need for therapies that target the root genetic cause of the disease.
Through this partnership, the companies will leverage Byongen’s proprietary DynEvoLib® platform—a high-throughput discovery engine combining computer-aided design with directed evolution—to identify novel AAV capsids with superior muscle-tropism and reduced immunogenicity. These next-generation vectors will be paired with Genecradle’s Smart-Dystrophin, an innovatively designed transgene optimized for enhanced biological activity and functional restoration.
"We are thrilled to join forces with Genecradle Therapeutics to tackle the delivery challenges inherent in treating DMD," said Gang Wang, Ph.D., Founder and CEO of Byongen Therapeutics. "By combining our highly muscle-tropic AAV capsids identified through DynEvoLib® with Genecradle’s sophisticated transgene designs, we aim to establish a new standard for precision and safety in gene therapies for neuromuscular disorders."
By integrating highly specific delivery vehicles with optimized expression cassettes, the collaboration aims to enhance therapeutic efficacy while potentially lowering the required systemic dose, thereby improving the overall safety profile for patients.
About Byongen Therapeutics
Byongen Therapeutics is a biotechnology company focused on original innovation in AAV delivery technologies. The company aims to address core clinical delivery bottlenecks through capsid engineering. By leveraging its proprietary DynEvoLib® platform, Byongen integrates AI, rational design, and high-throughput directed evolution to develop next-generation AAV capsids. Byongen’s R&D focus targets the development of specialized capsids for neuromuscular and central nervous system (CNS) diseases.
About Genecradle Therapeutics
Beijing Genecradle Therapeutics Technology Co., Ltd. is a national high-tech enterprise with core business in the development of gene therapy drugs mediated by AAV vector delivery technology. The company is committed to advancing rare disease gene drugs from the laboratory to clinical and market applications, benefiting patients and their families. It specializes in the development of gene therapy drugs for genetic neuromuscular diseases, inherited metabolic diseases, lysosomal diseases, and ophthalmic diseases. By promoting the research and clinical application of rare disease gene drugs, the company aims to deepen the understanding of health and life, transitioning gene therapy technology and products from rare diseases to the treatment and rehabilitation of chronic and other major diseases.
京公网安备11011502040057号
